Kronborg O
Department of Surgery, Odense University, Denmark.
Semin Surg Oncol. 1994 May-Jun;10(3):217-24. doi: 10.1002/ssu.2980100310.
Patients' benefit from follow-up examinations after curative surgery for colorectal cancer is unproven in spite of numerous different programs' having been designed for that purpose. Unfortunately, no final results from prospective randomized studies have been published yet and no ideal marker for recurrent cancer is available to identify patients in whom new curative treatment may be possible. So far, screening for metachronous neoplasia with intervals of several years may influence survival, whereas benefit from detecting recurrent colorectal cancer may be claimed only by using historical or other inappropriate controls. The tradition of follow-up is expensive and prospective evidence for any cost benefit is needed to justify continuous use of our limited resources in this area of patient care.
尽管已经设计了许多不同的方案用于此目的，但结直肠癌根治性手术后患者从随访检查中获得的益处尚未得到证实。不幸的是，前瞻性随机研究的最终结果尚未发表，并且没有理想的复发性癌症标志物可用于识别可能适合新的根治性治疗的患者。到目前为止，每隔几年进行一次异时性肿瘤筛查可能会影响生存率，而从检测复发性结直肠癌中获得的益处可能仅通过使用历史对照或其他不适当的对照来证明。随访的传统成本高昂，需要前瞻性证据来证明成本效益，以便在该患者护理领域合理持续使用我们有限的资源。
